The DOI matches its Crossref record; 268 of the 268 references it cites were found in a registry or an index.
Antibacterial Natural Products in Medicinal Chemistry—Exodus or Revival?
Abstract
To create a drug, nature's blueprints often have to be improved through semisynthesis or total synthesis (chemical postevolution). Selected contributions from industrial and academic groups highlight the arduous but rewarding path from natural products to drugs. Principle modification types for natural products are discussed herein, such as decoration, substitution, and degradation. The biological, chemical, and socioeconomic environments of antibacterial research are dealt with in context. Natural products, many from soil organisms, have provided the majority of lead structures for marketed anti‐infectives. Surprisingly, numerous “old” classes of antibacterial natural products have never been intensively explored by medicinal chemists. Nevertheless, research on antibacterial natural products is flagging. Apparently, the “old fashioned” natural products no longer fit into modern drug discovery. The handling of natural products is cumbersome, requiring nonstandardized workflows and extended timelines. Revisiting natural products with modern chemistry and target‐finding tools from biology (reversed genomics) is one option for their revival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds
Miyaura, N., & Suzuki, A. (1995) · Chemical Reviews · doi:10.1021/cr00039a007 · Cited by 12,817
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Whole-Genome Random Sequencing and Assembly of Haemophilus influenzae Rd
Fleischmann, R. D., Adams, M. D., White, O., Clayton, R. A., Kirkness, E. F., Kerlavage, A. R., Bult, C. J., Tomb, J.-F., Dougherty, B. A., Merrick, J. M., et al. (1995) · Science · doi:10.1126/science.7542800 · Cited by 5,654
Chopra, I., & Roberts, M. (2001) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.65.2.232-260.2001 · Cited by 4,517
Molecular Basis of Bacterial Outer Membrane Permeability Revisited
Nikaido, H. (2003) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.67.4.593-656.2003 · Cited by 4,316
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
Peptidoglycan types of bacterial cell walls and their taxonomic implications
Schleifer, K. H., & Kandler, O. (1972) · Bacteriological Reviews · doi:10.1128/mmbr.36.4.407-477.1972 · Cited by 4,223
Peptidoglycan types of bacterial cell walls and their taxonomic implications
Schleifer, K. H., & Kandler, O. (1972) · Bacteriological Reviews · doi:10.1128/br.36.4.407-477.1972 · Cited by 4,222
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Natural products as sources of new drugs over the period 1981–2002
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
The evolving role of natural products in drug discovery
Koehn, F. E., & Carter, G. T. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1657 · Cited by 2,572
The challenge of emerging and re-emerging infectious diseases
Morens, D. M., Folkers, G. K., & Fauci, A. S. (2004) · Nature · doi:10.1038/nature02759 · Cited by 2,103
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Inactivation of Antibiotics and the Dissemination of Resistance Genes
Davies, J. (1994) · Science · doi:10.1126/science.8153624 · Cited by 1,730
Carter, A. P., Clemons, W. M., Brodersen, D. E., Morgan-Warren, R. J., Wimberly, B. T., & Ramakrishnan, V. (2000) · Nature · doi:10.1038/35030019 · Cited by 1,615
Molecular mechanisms that confer antibacterial drug resistance
Walsh, C. (2000) · Nature · doi:10.1038/35021219 · Cited by 1,578
Accessing Genetic Information with High-Density DNA Arrays
Chee, M., Yang, R., Hubbell, E., Berno, A., Huang, X. C., Stern, D., Winkler, J., Lockhart, D. J., Morris, M. S., & Fodor, S. P. A. (1996) · Science · doi:10.1126/science.274.5287.610 · Cited by 1,489
Shevchenko, A., Jensen, O. N., Podtelejnikov, A. V., Sagliocco, F., Wilm, M., Vorm, O., Mortensen, P., Shevchenko, A., Boucherie, H., & Mann, M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.25.14440 · Cited by 1,427
The role of natural product chemistry in drug discovery
Butler, M. S. (2004) · Journal of Natural Products · doi:10.1021/np040106y · Cited by 1,381
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Growth of the Stress-Bearing and Shape-Maintaining Murein Sacculus of Escherichia coli
Höltje, J.-V. (1998) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.62.1.181-203.1998 · Cited by 1,129
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Schlünzen, F., Zarivach, R., Harms, J., Bashan, A., Tocilj, A., Albrecht, R., Yonath, A., & Franceschi, F. (2001) · Nature · doi:10.1038/35101544 · Cited by 1,059
Spratt, B. G. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.8.2999 · Cited by 971
Ribosome Structure and the Mechanism of Translation
Ramakrishnan, V. (2002) · Cell · doi:10.1016/s0092-8674(02)00619-0 · Cited by 938
Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'
Drusano, G. L. (2004) · Nature Reviews Microbiology · doi:10.1038/nrmicro862 · Cited by 930
Feher, M., & Schmidt, J. M. (2003) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci0200467 · Cited by 927
Bacterial Resistance to β-Lactam Antibiotics: Compelling Opportunism, Compelling Opportunity
Fisher, J. F., Meroueh, S. O., & Mobashery, S. (2005) · Chemical Reviews · doi:10.1021/cr030102i · Cited by 913
High Resolution Structure of the Large Ribosomal Subunit from a Mesophilic Eubacterium
Harms, J., Schluenzen, F., Zarivach, R., Bashan, A., Gat, S., Agmon, I., Bartels, H., Franceschi, F., & Yonath, A. (2001) · Cell · doi:10.1016/s0092-8674(01)00546-3 · Cited by 901
Genetic Analysis of a High-Level Vancomycin-Resistant Isolate of Staphylococcus aureus
Weigel, L. M., Clewell, D. B., Gill, S. R., Clark, N. C., McDougal, L. K., Flannagan, S. E., Kolonay, J. F., Shetty, J., Killgore, G. E., & Tenover, F. C. (2003) · Science · doi:10.1126/science.1090956 · Cited by 889
Increasing Prevalence of Multidrug-Resistant Streptococcus pneumoniae in the United States
Whitney, C. G., Farley, M. M., Hadler, J., Harrison, L. H., Lexau, C., Reingold, A., Lefkowitz, L., Cieslak, P. R., Cetron, M., Zell, E. R., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432603 · Cited by 888
Nomenclature for Macrolide and Macrolide-Lincosamide-Streptogramin B Resistance Determinants
Roberts, M. C., Sutcliffe, J., Courvalin, P., Jensen, L. B., Rood, J., & Seppala, H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.12.2823 · Cited by 874
Trends in antimicrobial drug development: Implications for the future
Spellberg, B., Powers, J. H., Brass, E. P., Miller, L. G., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/420937 · Cited by 867
Efflux-Mediated Drug Resistance in Bacteria
Li, X.-Z., & Nikaido, H. (2004) · Drugs · doi:10.2165/00003495-200464020-00004 · Cited by 798
Salgado, C. D., Farr, B. M., & Calfee, D. P. (2003) · Clinical Infectious Diseases · doi:10.1086/345436 · Cited by 790
Where will new antibiotics come from?
Walsh, C. (2003) · Nature Reviews Microbiology · doi:10.1038/nrmicro727 · Cited by 755
The future challenges facing the development of new antimicrobial drugs
Coates, A., Hu, Y., Bax, R., & Page, C. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd940 · Cited by 704
Lipid II as a target for antibiotics
Breukink, E., & de Kruijff, B. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2004 · Cited by 701
Glycopeptide and Lipoglycopeptide Antibiotics
Kahne, D., Leimkuhler, C., Lu, W., & Walsh, C. (2005) · Chemical Reviews · doi:10.1021/cr030103a · Cited by 662
Bugg, T. D. H., Wright, G. D., Dutka-Malen, S., Arthur, M., Courvalin, P., & Walsh, C. T. (1991) · Biochemistry · doi:10.1021/bi00107a007 · Cited by 650
Antibiotics: Actions, Origins, Resistance
Walsh, C. (2003) · Wiley eBooks · doi:10.1128/9781555817886 · Cited by 633
Lewis, K. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.3.503-514.2000 · Cited by 616
Large-scale manufacture of peptide therapeutics by chemical synthesis
Bray, B. L. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1133 · Cited by 598
The Structure of ClpP at 2.3 Å Resolution Suggests a Model for ATP-Dependent Proteolysis
Wang, J., Hartling, J. A., & Flanagan, J. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80431-6 · Cited by 591
Bacterial Resistance: Origins, Epidemiology, and Impact
Livermore, D. M. (2003) · Clinical Infectious Diseases · doi:10.1086/344654 · Cited by 586
Oxazolidinone Structure–Activity Relationships Leading to Linezolid
Barbachyn, M. R., & Ford, C. W. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200528 · Cited by 553
Koch, M. A., Schuffenhauer, A., Scheck, M., Wetzel, S., Casaulta, M., Odermatt, A., Ertl, P., & Waldmann, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503647102 · Cited by 544
Doern, G. V., Heilmann, K. P., Huynh, H. K., Rhomberg, P. R., Coffman, S. L., & Brueggemann, A. B. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1721-1729.2001 · Cited by 538
Target-based drug discovery: is something wrong?
Sams-Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522
Natural Product Hybrids as New Leads for Drug Discovery
Tietze, L. F., Bell, H. P., & Chandrasekhar, S. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200553 · Cited by 516
KAHAN, J. S., KAHAN, F. M., GOEGELMAN, R., CURRIE, S. A., JACKSON, M., STAPLEY, E. O., MILLER, T. W., MILLER, A. K., HENDLIN, D., MOCHALES, S., et al. (1979) · The Journal of Antibiotics · doi:10.7164/antibiotics.32.1 · Cited by 514
Dysregulation of bacterial proteolytic machinery by a new class of antibiotics
Brötz-Oesterhelt, H., Beyer, D., Kroll, H.-P., Endermann, R., Ladel, C., Schroeder, W., Hinzen, B., Raddatz, S., Paulsen, H., Henninger, K., et al. (2005) · Nature Medicine · doi:10.1038/nm1306 · Cited by 505
Self-citationWhy is big Pharma getting out of antibacterial drug discovery?
Projan, S. J. (2003) · Current Opinion in Microbiology · doi:10.1016/j.mib.2003.08.003 · Cited by 503
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Trends in Infectious Diseases Mortality in the United States
Pinner, R. W. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03530270029027 · Cited by 487
Davis, M. S., Solbiati, J., & Cronan, J. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004756200 · Cited by 479
Breinbauer, R., Vetter, I. R., & Waldmann, H. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020816)41:16<2878::aid-anie2878>3.0.co;2-b · Cited by 475
The Vancomycin Group of Antibiotics and the Fight against Resistant Bacteria
Williams, D. H., & Bardsley, B. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990503)38:9<1172::aid-anie1172>3.0.co;2-c · Cited by 468
Natural products ? a simple model to explain chemical diversity
Firn, R. D., & Jones, C. G. (2003) · Natural Product Reports · doi:10.1039/b208815k · Cited by 467
Retsema, J., Girard, A., Schelkly, W., Manousos, M., Anderson, M., Bright, G., Borovoy, R., Brennan, L., & Mason, R. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.12.1939 · Cited by 464
Sulfoxide-Carbodiimide Reactions. I. A Facile Oxidation of Alcohols
Pfitzner, K. E., & Moffatt, J. G. (1965) · Journal of the American Chemical Society · doi:10.1021/ja00952a026 · Cited by 458
Lambert, P. A. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.7.x · Cited by 450
Lim, D., & Strynadka, N. C. J. (2002) · Nature Structural Biology · doi:10.1038/nsb858 · Cited by 442
Higgins, D. L., Chang, R., Debabov, D. V., Leung, J., Wu, T., Krause, K. M., Sandvik, E., Hubbard, J. M., Kaniga, K., Schmidt, D. E., et al. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.3.1127-1134.2005 · Cited by 425
Lysobacter, a New Genus of Nonfruiting, Gliding Bacteria with a High Base Ratio
CHRISTENSEN, P., & Cook, F. D. (1978) · International Journal of Systematic Bacteriology · doi:10.1099/00207713-28-3-367 · Cited by 413
Animal model pharmacokinetics and pharmacodynamics: a critical review
Andes, D., & Craig, W. A. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(02)00022-5 · Cited by 413
Selection criteria for drug‐like compounds
Muegge, I. (2003) · Medicinal Research Reviews · doi:10.1002/med.10041 · Cited by 412
Nathan, C. (2004) · Nature · doi:10.1038/431899a · Cited by 410
Vancomycin-resistant enterococci: why are they here, and where do they come from?
Bonten, M. J., Willems, R., & Weinstein, R. A. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00145-1 · Cited by 400
Naturally-occurring beta-lactamase inhibitors with antibacterial activity
BROWN, A. G., BUTTERWORTH, D., COLE, M., HANSCOMB, G., HOOD, J. D., READING, C., & ROLINSON, G. N. (1976) · The Journal of Antibiotics · doi:10.7164/antibiotics.29.668 · Cited by 399
Eliopoulos, G. M., & Bush, K. (2001) · Clinical Infectious Diseases · doi:10.1086/319610 · Cited by 392
Proteomic Approach to Understanding Antibiotic Action
Bandow, J. E., Brötz, H., Leichert, L. I. O., Labischinski, H., & Hecker, M. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.948-955.2003 · Cited by 391
Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story
Walsh, C. T., Fisher, S. L., Park, I.-S., Prahalad, M., & Wu, Z. (1996) · Chemistry & Biology · doi:10.1016/s1074-5521(96)90079-4 · Cited by 387
Root of the universal tree of life based on ancient aminoacyl-tRNA synthetase gene duplications.
Brown, J. R., & Doolittle, W. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.7.2441 · Cited by 377
Vancomycin Assembly: Nature's Way
Hubbard, B. K., & Walsh, C. T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200390202 · Cited by 356
Kropp, H., Sundelof, J. G., Hajdu, R., & Kahan, F. M. (1982) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.22.1.62 · Cited by 339
Sulfazecin and isosulfazecin, novel β-lactam antibiotics of bacterial origin
Imada, A., Kitano, K., Kintaka, K., Muroi, M., & Asai, M. (1981) · Nature · doi:10.1038/289590a0 · Cited by 335
Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis
Rock, C. O., & Cronan, J. E. (1996) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(96)00056-2 · Cited by 332
Eady, E. A., & Cove, J. H. (2003) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200304000-00007 · Cited by 329
MCGUIRE, J. M., BUNCH, R. L., ANDERSON, R. C., Boaz, H. E., Flynn, E. H., POWELL, H. M., & SMITH, J. W. (1952) · PubMed · Cited by 326
Carbapenemases: a problem in waiting?
Livermore, D. M., & Woodford, N. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00128-4 · Cited by 323
Preventing drug access to targets: cell surface permeability barriers and active efflux in bacteria
Nikaido, H. (2001) · Seminars in Cell & Developmental Biology · doi:10.1006/scdb.2000.0247 · Cited by 317
Thienamycin: development of imipenem-cilastatin
Kahan, F. M., Kropp, H., Sundelof, J. G., & Birnbaum, J. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.suppl_d.1 · Cited by 313
Pankey, G. A. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki248 · Cited by 301
Bugg, T. D. H., & Walsh, C. T. (1992) · Natural Product Reports · doi:10.1039/np9920900199 · Cited by 300
Structure and absolute configuration of thienamycin
Albers-Schoenberg, G., Arison, B. H., Hensens, O. D., Hirshfield, J. M., Hoogsteen, K., Kaczka, E. A., Rhodes, R. E., Kahan, J. S., & Kahan, F. M. (1978) · Journal of the American Chemical Society · doi:10.1021/ja00488a038 · Cited by 299
A Convergent Enantioselective Route to Structurally Diverse 6-Deoxytetracycline Antibiotics
Charest, M. G., Lerner, C. D., Brubaker, J. D., Siegel, D. R., & Myers, A. G. (2005) · Science · doi:10.1126/science.1109755 · Cited by 298
mefE is necessary for the erythromycin-resistant M phenotype in Streptococcus pneumoniae
Tait-Kamradt, A., Clancy, J., Cronan, M., Dib-Hajj, F., Wondrack, L., Yuan, W., & Sutcliffe, J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.10.2251 · Cited by 298
Structure of vancomycin and its complex with acetyl-D-alanyl-D-alanine
Sheldrick, G. M., Jones, P. G., Kennard, O., Williams, D. H., & Smith, G. A. (1978) · Nature · doi:10.1038/271223a0 · Cited by 297
Education reforms struggle against apartheid's legacy
(1996) · Nature · doi:10.1038/384014a0 · Cited by 291
Trias, J., & Nikaido, H. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.1.52 · Cited by 291
Hansen, L. H., Mauvais, P., & Douthwaite, S. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01202.x · Cited by 291
Vancomycin Assembly: Nature′s Way
Hubbard, B. K., & Walsh, C. T. (2003) · ChemInform · doi:10.1002/chin.200322284 · Cited by 290
Clindamycin-Associated Colitis
Cohen, L. E. (1973) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1973.03220120045012 · Cited by 280
SnB: crystal structure determination via shake-and-bake
Miller, R., Gallo, S. M., Khalak, H. G., & Weeks, C. M. (1994) · Journal of Applied Crystallography · doi:10.1107/s0021889894000191 · Cited by 278
Mechanism of action of oritavancin and related glycopeptide antibiotics
Allen, N. (2003) · FEMS Microbiology Reviews · doi:10.1016/s0168-6445(02)00144-4 · Cited by 276
A genome-based approach for the identification of essential bacterial genes
Arigoni, F., Talabot, F., Peitsch, M., Edgerton, M. D., Meldrum, E., Allet, E., Fish, R., Jamotte, T., Curchod, M.-L., & Loferer, H. (1998) · Nature Biotechnology · doi:10.1038/nbt0998-851 · Cited by 269
Total Syntheses of Vancomycin and Eremomycin Aglycons
Evans, D. A., Wood, M. R., Trotter, B. W., Richardson, T. I., Barrow, J. C., & Katz, J. L. (1998) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19981016)37:19<2700::aid-anie2700>3.0.co;2-p · Cited by 268
Trends in development and approval times for new therapeutics in the United States
Reichert, J. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1178 · Cited by 260
Vollmer, W., & Höltje, J.-V. (2004) · Journal of Bacteriology · doi:10.1128/jb.186.18.5978-5987.2004 · Cited by 258
The Impact of Bacterial Genomics on Natural Product Research
Bode, H. B., & Müller, R. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501080 · Cited by 253
Drugs, leads, and drug-likeness: an analysis of some recently launched drugs
Proudfoot, J. R. (2002) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(02)00244-5 · Cited by 252
Aminoglycoside-modifying enzymes
Wright, G. D. (1999) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(99)00007-7 · Cited by 241
Antimicrobial susceptibility of coagulase-negative staphylococci
Archer, G. L., & Climo, M. W. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.10.2231 · Cited by 237
Manipulation of Modular Polyketide Synthases
Katz, L. (1997) · Chemical Reviews · doi:10.1021/cr960025+ · Cited by 235
MORIMOTO, S., TAKAHASHI, Y., WATANABE, Y., & OMURA, S. (1984) · The Journal of Antibiotics · doi:10.7164/antibiotics.37.187 · Cited by 233
From protein domains to drug candidates – natural products as guiding principles in
Breinbauer, R., Vetter, I., & Waldmann, H. (2002) · Angewandte Chemie International Edition · doi:10.1002/1521-3773(20020816)41:16<2878::aid-anie2878>3.0.co;2 · Cited by 231
The Antibiotic Pipeline — Challenges, Costs, and Values
Wenzel, R. P. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048093 · Cited by 230
Leeb, M. (2004) · Nature · doi:10.1038/431892a · Cited by 225
Tuberculosis Drug Resistance: A Global Threat
Nachega, J. B., & Chaisson, R. E. (2003) · Clinical Infectious Diseases · doi:10.1086/344657 · Cited by 225
Antibiotics: Where did we go wrong?
Overbye, K. M., & Barrett, J. F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03285-4 · Cited by 223
A comprehensive two-dimensional map of cytosolic proteins ofBacillus subtilis
Büttner, K., Bernhardt, J., Scharf, C., Schmid, R., Mäder, U., Eymann, C., Antelmann, H., Völker, A., Völker, U., & Hecker, M. (2001) · ELECTROPHORESIS · doi:10.1002/1522-2683(200108)22:14<2908::aid-elps2908>3.0.co;2-m · Cited by 222
Freiberg, C., Brunner, N. A., Schiffer, G., Lampe, T., Pohlmann, J., Brands, M., Raabe, M., Häbich, D., & Ziegelbauer, K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402989200 · Cited by 218
Self-citationGlycopeptide Antibiotics: from Conventional Molecules to New Derivatives
Van Bambeke, F., Van Laethem, Y., Courvalin, P., & Tulkens, P. M. (2004) · Drugs · doi:10.2165/00003495-200464090-00001 · Cited by 213
Asymmetric total synthesis of erythromycin. 3. Total synthesis of erythromycin
Woodward, R. B., Logusch, E., Nambiar, K. P., Sakan, K., Ward, D. E., Au-Yeung, B. W., Balaram, P., Browne, L. J., Card, P. J., & Chen, C. H. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00401a051 · Cited by 205
Managing Antibiotic Resistance
Wenzel, R. P., & Edmond, M. B. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012283432610 · Cited by 204
Crystal structure of vancomycin
Schäfer, M., Schneider, T. R., & Sheldrick, G. M. (1996) · Structure · doi:10.1016/s0969-2126(96)00156-6 · Cited by 203
Total Synthesis of the Vancomycin Aglycon
Boger, D. L., Miyazaki, S., Kim, S. H., Wu, J. H., Castle, S. L., Loiseleur, O., & Jin, Q. (1999) · Journal of the American Chemical Society · doi:10.1021/ja992577q · Cited by 201
Agouridas, C., Denis, A., Auger, J.-M., Benedetti, Y., Bonnefoy, A., Bretin, F., Chantot, J., Dussarat, A., Fromentin, C., D'Ambrières, S. G., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm980240d · Cited by 201
White, A. R. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh050 · Cited by 198
Denis, A., Agouridas, C., Auger, J.-M., Benedetti, Y., Bonnefoy, A., Bretin, F., Chantot, J.-F., Dussarat, A., Fromentin, C., Gouin D'Ambrières, S., et al. (1999) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(99)00534-x · Cited by 196
Piperacillin/Tazobactam: An Updated Review of its Use in the Treatment of Bacterial Infections
Perry, C. M., & Markham, A. (1999) · Drugs · doi:10.2165/00003495-199957050-00017 · Cited by 193
Nicolaou, K. C., Mitchell, H. J., Jain, N. F., Winssinger, N., Hughes, R. O., & Bando, T. (1999) · Angewandte Chemie International Edition · Cited by 187
The Diagnosis and Therapy of Tuberculosis During the Past 100 Years
Mitchison, D. A. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200411-1603oe · Cited by 185
The Ketolides: A Critical Review
Zhanel, G. G., Walters, M., Noreddin, A., Vercaigne, L. M., Wierzbowski, A., Embil, J. M., Gin, A. S., Douthwaite, S., & Hoban, D. J. (2002) · Drugs · doi:10.2165/00003495-200262120-00006 · Cited by 183
Reductive Alkylation of Glycopeptide Antibiotics: Synthesis and Antibacterial Activity.
COOPER, R. D. G., SNYDER, N. J., ZWEIFEL, M. J., STASZAK, M. A., WILKIE, S. C., NICAS, T. I., MULLEN, D. L., BUTLER, T. F., RODRIGUEZ, M. J., HUFF, B. E., et al. (1996) · The Journal of Antibiotics · doi:10.7164/antibiotics.49.575 · Cited by 181
Li, X.-Z., Zhang, L., & Poole, K. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.4.433 · Cited by 176
Mechanisms of resistance to antibiotics
Wright, G. D. (2003) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2003.08.004 · Cited by 175
Ma, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
High-throughput drug discovery: What can we expect from HTS?
Gribbon, P., & Andreas, S. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03275-1 · Cited by 174
Total synthesis of erythromycins. 5. Total synthesis of erythronolide A
Corey, E. J., Hopkins, P. B., Kim, S., Yoo, S.-E., Nambiar, K. P., & Falck, J. R. (1979) · Journal of the American Chemical Society · doi:10.1021/ja00517a088 · Cited by 171
Discovery of a Novel and Potent Class of FabI-Directed Antibacterial Agents
Payne, D. J., Miller, W. H., Berry, V., Brosky, J., Burgess, W. J., Chen, E., DeWolf, W. E., Fosberry, A. P., Greenwood, R., Head, M. S., et al. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.10.3118-3124.2002 · Cited by 170
Macrolides, chemistry, pharmacology and clinical uses
Vanderhaeghe, H., & Hoogmartens, J. (1993) · Cited by 170
Pneumococcal macrolide resistance—myth or reality?
Amsden, G. W. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.1.1 · Cited by 169
Antimicrobial resistance among gram-negative organisms in the intensive care unit
Clark, N. M., PATTERSON, J. E., & Lynch, J. P. (2003) · Current Opinion in Critical Care · doi:10.1097/00075198-200310000-00012 · Cited by 168
McComas, C. C., Crowley, B. M., & Boger, D. L. (2003) · Journal of the American Chemical Society · doi:10.1021/ja035901x · Cited by 166
Strategic trends in the drug industry
Drews, J. (2003) · Drug Discovery Today · doi:10.1016/s1359-6446(03)02690-4 · Cited by 165
Hydrophobic Vancomycin Derivatives with Improved ADME Properties: Discovery of Telavancin (TD-6424)
LEADBETTER, M. R., ADAMS, S. M., BAZZINI, B., FATHEREE, P. R., KARR, D. E., KRAUSE, K. M., LAM, B. M. T., LINSELL, M. S., NODWELL, M. B., PACE, J. L., et al. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.326 · Cited by 165
Howarth, T. T., Brown, A. G., & King, T. J. (1976) · J. Chem. Soc., Chem. Commun. · doi:10.1039/c3976000266b · Cited by 162
Cassell, G. H. (2001) · JAMA · doi:10.1001/jama.285.5.601 · Cited by 162
Clinical strain of Staphylococcus aureus inactivates and causes efflux of macrolides
Wondrack, L. M., Massa, M. A., Yang, B. V., & Sutcliffe, J. A. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.992 · Cited by 162
Hakenbeck, R., Grebe, T., Zähner, D., & Stock, J. B. (1999) · Molecular Microbiology · doi:10.1046/j.1365-2958.1999.01521.x · Cited by 161
Srikumar, R., Paul, C. J., & Poole, K. (2000) · Journal of Bacteriology · doi:10.1128/jb.182.5.1410-1414.2000 · Cited by 160
Dead Bugs Don’t Mutate: Susceptibility Issues in the Emergence of Bacterial Resistance
Stratton, C. W. (2003) · Emerging infectious diseases · doi:10.3201/eid0901.020172 · Cited by 159
Erythromycin. X.1 Structure of Erythromycin
Wiley, P. F., Gerzon, K., Flynn, E. H., Sigal, M. V., Weaver, O., Quarck, U. C., Chauvette, R. R., & Monahan, R. (1957) · Journal of the American Chemical Society · doi:10.1021/ja01579a059 · Cited by 155
[23] Endopeptidase Clp: ATP-dependent Clp protease from Escherichia coli
Maurizi, M. R., Thompson, M. W., Singh, S. K., & Kim, S. (1994) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/0076-6879(94)44025-5 · Cited by 154
Exploiting current understanding of antibiotic action for discovery of new drugs
Chopra, I., Hesse, L., & O’Neill, A. J. (2002) · Journal of Applied Microbiology · doi:10.1046/j.1365-2672.92.5s1.13.x · Cited by 154
Prediction of Mechanisms of Action of Antibacterial Compounds by Gene Expression Profiling
Hutter, B., Schaab, C., Albrecht, S., Borgmann, M., Brunner, N. A., Freiberg, C., Ziegelbauer, K. B., Rock, C. O., Ivanov, I., & Loferer, H. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.2838-2844.2004 · Cited by 153
Synthesis of Polyethylene Glycol (PEG) Derivatives and PEGylated−Peptide Biopolymer Conjugates
Li, J., & Kao, W. J. (2003) · Biomacromolecules · doi:10.1021/bm034069l · Cited by 152
Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits
Wunberg, T., Hendrix, M., Hillisch, A., Lobell, M., Meier, H., Schmeck, C., Wild, H., & Hinzen, B. (2006) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03700-1 · Cited by 152
Self-citationGenetic strategies for antibacterial drug discovery
Miesel, L., Greene, J. R., & Black, T. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1086 · Cited by 152
Raja, A., LaBonte, J. A., Lebbos, J., & Kirkpatrick, P. N. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1258 · Cited by 151
In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic
Candiani, G., Abbondi, M., Borgonovi, M., Romanò, G., & Parenti, F. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/44.2.179 · Cited by 150
The Ribosome through the Looking Glass
Wilson, D. N., & Nierhaus, K. H. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200544 · Cited by 147
Crowley, B. M., & Boger, D. L. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0572912 · Cited by 145
Structural modifications of glycopeptide antibiotics
Malabarba, A., Nicas, T. I., & Thompson, R. C. (1997) · Medicinal Research Reviews · Cited by 140
Needham, J., Kelly, M. T., Ishige, M., & Andersen, R. J. (1994) · The Journal of Organic Chemistry · doi:10.1021/jo00087a020 · Cited by 139
Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci
Sundram, U. N., Griffin, J. H., & Nicas, T. I. (1996) · Journal of the American Chemical Society · doi:10.1021/ja9621298 · Cited by 136
Hoban, D. J., Biedenbach, D. J., Mutnick, A. H., & Jones, R. N. (2003) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(02)00540-0 · Cited by 136
The $800 million pill: the truth behind the cost of new drugs
(2005) · Choice Reviews Online · doi:10.5860/choice.42-5898 · Cited by 135
Pharmacodynamics of Telavancin (TD-6424), a Novel Bactericidal Agent, against Gram-Positive Bacteria
Hegde, S. S., Reyes, N., Wiens, T., Vanasse, N., Skinner, R., McCullough, J. L., Kaniga, K., Pace, J., Thomas, R., Shaw, J., et al. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.8.3043-3050.2004 · Cited by 135
Diastereoselective Total Synthesis of the Vancomycin Aglycon with Ordered Atropisomer Equilibrations
Boger, D. L., Miyazaki, S., Kim, S. H., Wu, J. H., Loiseleur, O., & Castle, S. L. (1999) · Journal of the American Chemical Society · doi:10.1021/ja990189i · Cited by 133
Nicolaou, K. C., Hughes, R. O., Cho, S. Y., Winssinger, N., Smethurst, C., Labischinski, H., & Endermann, R. (2000) · Angewandte Chemie International Edition · Cited by 132
Vancomycin resistance: occurrence, mechanisms and strategies to combat it
Boneca, I. G., & Chiosis, G. (2003) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.7.3.311 · Cited by 131
On the Remarkable Antitumor Properties of Fludelone: How We Got There
Rivkin, A., Chou, T., & Danishefsky, S. J. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200461751 · Cited by 130
Wise, R. A. (1983) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/12.1.1 · Cited by 129
β-Lactams in the New Millennium. Part-II: Cephems, Oxacephems, Penams and Sulbactam
Singh, G. S. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487547 · Cited by 129
Williamson, M. P., & Williams, D. H. (1981) · Journal of the American Chemical Society · doi:10.1021/ja00412a008 · Cited by 127
Recent developments in carbapenems
Nicoletti, G., Russo, G., & Bonfiglio, G. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.4.529 · Cited by 125
Nicolaou, K. C., Hughes, R. O., Cho, S. Y., Winssinger, N., Smethurst, C. A., Labischinski, H., & Endermann, R. (2000) · Angewandte Chemie · Cited by 124
Glycopeptides in clinical development: pharmacological profile and clinical perspectives
Françoise Van Bambeke, A. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.04.006 · Cited by 123
New (and not so new) antibacterial targets – from where and when will the novel drugs come?
Projan, S. J. (2002) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(02)00197-2 · Cited by 122
Hiramatsu, K., Okuma, K., Xue, X., Yamamoto, M., Hori, S., & Kapi, M. (2002) · Current Opinion in Infectious Diseases · doi:10.1097/00001432-200208000-00009 · Cited by 121
Total Synthesis of Vancomycin Aglycon—Part 3: Final Stages
Nicolaou, K. C., Takayanagi, M., Jain, N. F., Natarajan, S., Koumbis, A. E., Bando, T., & Ramanjulu, J. M. (1998) · Angewandte Chemie International Edition · Cited by 120
Ma, Z., Clark, R. F., Brazzale, A., Wang, S., Rupp, M., Li, L., Griesgraber, G. W., Zhang, S., Yong, H., Phan, L., et al. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm0102349 · Cited by 120
Goozner, M. (2004) · University of California Press eBooks · doi:10.1525/9780520939288 · Cited by 120
Multitargeted drugs: the end of the ‘one-target-one-disease’ philosophy?
Wermuth, C. G. (2004) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03213-1 · Cited by 114
King, A., Phillips, I., & Kaniga, K. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh156 · Cited by 114
REDISCOVERING NATURAL PRODUCTS
ROUHI, A. M. (2003) · Chemical & Engineering News · doi:10.1021/cen-v081n041.p077 · Cited by 112
Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., & Fernandez, H. T. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.6.2149-2152.2004 · Cited by 108
Decreased outer membrane permeability in imipenem-resistant mutants of Pseudomonas aeruginosa
Trias, J., Dufresne, J., Lévesque, R. C., & Nikaido, H. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.8.1202 · Cited by 105
Freiberg, C., Fischer, H. P., & Brunner, N. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.749-759.2005 · Cited by 105
Or, Y. S., Clark, R. F., Wang, S., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990618n · Cited by 104
Screening of natural products for antimicrobial agents
Silver, L. L., & Bostian, K. A. (1990) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01964283 · Cited by 104
Maki, H., Miura, K., & Yamano, Y. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1823-1827.2001 · Cited by 103
Introduction: Polyketide and Nonribosomal Polypeptide Biosynthesis. From Collie to Coli
Cane, D. E. (1997) · Chemical Reviews · doi:10.1021/cr970097g · Cited by 102
Respiratory Virus Infections in Adults with Hematologic Malignancies: A Prospective Study
Martino, R., Rámila, E., Rabella, N., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/344899 · Cited by 99
Recent Developments in Depsipeptide Research
Ballard, C. E., Yu, H., & Wang, B. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023371049 · Cited by 99
The structure and stereochemistry of erythromycin A.
Harris, D. R., McGeachin, S. G., & Mills, H. H. (1965) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)90018-2 · Cited by 97
Keynote review: Is declining innovation in the pharmaceutical industry a myth?
Schmid, E. F., & Smith, D. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03524-5 · Cited by 96
Kato, S., Kawai, H., KAWASAKI, T., et al. (1989) · The Journal of Antibiotics · doi:10.7164/antibiotics.42.1879 · Cited by 94
Medicinal Chemistry Optimization of Acyldepsipeptides of the Enopeptin Class Antibiotics
Hinzen, B., Raddatz, S., Paulsen, H., Lampe, T. F. J., Schumacher, A., Häbich, D., Hellwig, V., Benet‐Buchholz, J., Endermann, R., Labischinski, H., et al. (2006) · ChemMedChem · doi:10.1002/cmdc.200600055 · Cited by 93
Self-citationResistance to β-Lactam Antibiotics: Structure and Mechanism Based Design of β-Lactamase Inhibitors
Sandanayaka, V. P., & Prashad, A. S. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867023370031 · Cited by 90
Antibacterial drug discovery and structure-based design
Barker, J. J. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.03.001 · Cited by 88
Surviving the Blockbuster Syndrome
Service, R. F. (2004) · Science · doi:10.1126/science.303.5665.1796 · Cited by 86
Thomson, C. J., Power, E., Rübsamen‐Waigmann, H., & Labischinski, H. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.009 · Cited by 84
The impact of transcriptome and proteome analyses on antibiotic drug discovery
Freiberg, C., Brötz‐Oesterhelt, H., & Labischinski, H. (2004) · Current Opinion in Microbiology · doi:10.1016/j.mib.2004.08.010 · Cited by 83
Syntheses around the Transglycosylation Step in Peptidoglycan Biosynthesis
Welzel, P. (2005) · Chemical Reviews · doi:10.1021/cr040634e · Cited by 78
Cited by
Antibacterial properties of nanoparticles
Hajipour, M. J., Fromm, K. M., Akbar Ashkarran, A., Jimenez de Aberasturi, D., Larramendi, I. R. D., Rojo, T., Serpooshan, V., Parak, W. J., & Mahmoudi, M. (2012) · Trends in Biotechnology · doi:10.1016/j.tibtech.2012.06.004 · Cited by 2,710
A Historical Overview of Natural Products in Drug Discovery
Dias, D. A., Urban, S., & Roessner, U. (2012) · Metabolites · doi:10.3390/metabo2020303 · Cited by 1,958
Antibiotics for Emerging Pathogens
Fischbach, M. A., & Walsh, C. T. (2009) · Science · doi:10.1126/science.1176667 · Cited by 1,777
Electrifying Organic Synthesis
Wiebe, A., Gieshoff, T., Möhle, S., Rodrigo, E., Zirbes, M., & Waldvogel, S. R. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201711060 · Cited by 1,530
Thoughts and facts about antibiotics: Where we are now and where we are heading
Bérdy, J. (2012) · The Journal of Antibiotics · doi:10.1038/ja.2012.27 · Cited by 1,165
Metadata
- Authors
- von Nussbaum, F., Brands, M., Hinzen, B., Weigand, S., & Häbich, D.
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2006-07-31
- Volume
- 45
- Issue
- 31
- Pages
- 5072-5129
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2016567759
- Cited by
- 672
- References
- 268
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.